Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Tuesday that it has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for approval of IMAAVY (nipocalimab-aahu) as the first-ever treatment for patients with warm autoimmune haemolytic anaemia (wAIHA).
wAIHA is a rare, life-threatening condition where autoantibodies attach to and destroy red blood cells, resulting in anaemia. Additionally, people with wAIHA are at increased risk of other serious complications such as venous thrombotic events, acute renal failure, and infection. It affects approximately 1 in 8,000 people in the United States.
The sBLA submission is supported by the Phase 2/3 ENERGY multicentre, randomised, double-blind, placebo-controlled study evaluating IMAAVY in adults living with wAIHA. Data showed that more patients treated with nipocalimab achieved the stringent primary endpoint of a durable haemoglobin response compared with placebo.
FDA approves Genentech's Enspryng as first at-home subcutaneous treatment for thyroid eye disease
argenx reports positive Phase 2 results for FB102 in coeliac disease
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
Abogen enters Novartis licensing and option agreement to advance RNA programs
Ascletis reports positive results from ASC50 clinical study for treatment of plaque psoriasis
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma